Head-to-head evidence
Sarilumab vs tocilizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline
Sarilumab
Marketed by Sanofi and partners
NCT01061736 · Phase 2/3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
tocilizumab · Actemra / RoActemra
Marketed by Roche and partners
NCT03155347 · Phase 3 · completed
This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.
Next expected readout: August 2028 · NCT05869955 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sarilumab's landscape · tocilizumab's landscape